Ninety One UK Ltd Purchases 10,930 Shares of Danaher Co. (NYSE:DHR)

Ninety One UK Ltd grew its position in Danaher Co. (NYSE:DHR) by 10.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 119,794 shares of the conglomerate’s stock after acquiring an additional 10,930 shares during the period. Ninety One UK Ltd’s holdings in Danaher were worth $27,713,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Banco Santander S.A. bought a new stake in Danaher in the third quarter valued at approximately $683,000. First Citizens Bank & Trust Co. raised its stake in Danaher by 0.6% in the 4th quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock valued at $6,156,000 after acquiring an additional 149 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in Danaher by 48.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock valued at $68,707,000 after purchasing an additional 96,395 shares during the last quarter. Parkside Financial Bank & Trust boosted its position in Danaher by 4.8% during the third quarter. Parkside Financial Bank & Trust now owns 3,080 shares of the conglomerate’s stock worth $764,000 after purchasing an additional 142 shares during the period. Finally, Keybank National Association OH increased its holdings in shares of Danaher by 0.5% in the third quarter. Keybank National Association OH now owns 553,155 shares of the conglomerate’s stock valued at $137,238,000 after purchasing an additional 2,567 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently commented on DHR. Citigroup lifted their target price on shares of Danaher from $255.00 to $280.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Royal Bank of Canada boosted their price objective on Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. HSBC upgraded Danaher from a “hold” rating to a “buy” rating and boosted their price target for the company from $250.00 to $280.00 in a research note on Wednesday. Finally, Barclays increased their price objective on Danaher from $240.00 to $260.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 10th. Six equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and an average price target of $268.27.

Danaher Trading Down 1.3 %

Shares of DHR opened at $236.37 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.37 and a current ratio of 1.68. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $259.00. The firm has a market cap of $175.04 billion, a price-to-earnings ratio of 36.99, a PEG ratio of 3.64 and a beta of 0.83. The business’s fifty day moving average is $249.09 and its 200-day moving average is $229.90.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.18. The firm had revenue of $6.41 billion for the quarter, compared to analysts’ expectations of $6.10 billion. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The business’s revenue for the quarter was down 10.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.87 earnings per share. Equities analysts anticipate that Danaher Co. will post 7.62 EPS for the current fiscal year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Thursday, March 28th will be paid a $0.27 dividend. This is an increase from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date is Wednesday, March 27th. This represents a $1.08 annualized dividend and a yield of 0.46%. Danaher’s dividend payout ratio is presently 16.90%.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 3,289 shares of the company’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total transaction of $816,724.48. Following the completion of the transaction, the director now directly owns 19,726 shares in the company, valued at $4,898,360.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Danaher news, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the sale, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Teri List sold 3,289 shares of Danaher stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the transaction, the director now owns 19,726 shares in the company, valued at approximately $4,898,360.32. The disclosure for this sale can be found here. Insiders have sold 32,957 shares of company stock worth $8,265,802 over the last quarter. Corporate insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.